BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:11 PM
 | 
Oct 21, 2008
 |  BC Extra  |  Top Story

FDA panel backs Myozyme 2000 L

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 16-1 Tuesday that Genzyme (NASDAQ:GENZ) has demonstrated the safety and efficacy of Myozyme alglucosidase manufactured in a 2000-liter bioreactor to treat Pompe's disease. Thirteen voting members favored accelerated approval,...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >